Salbutamol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Bronchodilator
Subclass
Short-acting β2-adrenergic receptor agonist (SABA)
Speciality
Pulmonology
Schedule (India)
Schedule H
Routes
Oral, Inhalation (MDI, DPI, Nebuliser), Parenteral (IV, SC)
Formulations
- Inhaler (MDI): 100 mcg/actuation
- Dry Powder Inhaler (DPI): 200 mcg/dose (Rotacaps, Accuhaler)
- Nebuliser solution: 5 mg/mL respules; 2.5 mg/2.5 mL unit dose vials
- Tablets: 2 mg, 4 mg
- Oral syrup: 2 mg/5 mL
- Injection (IV/SC): 500 mcg/mL (as sulphate)
Adult indications
INDICATIONS + DOSING ā FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Acute Bronchospasm (Asthma Exacerbation, COPD Exacerbation)
Inhalation is the preferred route for rapid bronchodilation with fewer systemic effects.
| Route | Starting Dose | Titration | Usual Maintenance Dose | Maximum Dose | Clinical Notes |
|---|---|---|---|---|---|
|
MDI (100 mcg/puff)
|
2 puffs (200 mcg) | May repeat every 20 min × 3 doses in acute attack | 1ā2 puffs every 4ā6 hours PRN | 8ā12 puffs/day | Use spacer device for optimal lung deposition |
|
Nebulised
|
2.5 mg in 3 mL NS | May repeat every 20 min × 3 doses in acute setting | 2.5ā5 mg every 4ā6 hours | 40 mg/day (divided doses) | Continuous nebulisation in severe cases under monitoring |
|
SC Injection
|
250 mcg | May repeat after 4 hours | 250ā500 mcg every 4ā6 hours | 500 mcg every 4 hours | Reserve for situations where inhalation not feasible |
|
IV Infusion
|
5 mcg/min | Increase by 1ā2 mcg/min every 15ā30 min | 3ā20 mcg/min | 20 mcg/min | ICU setting only; continuous cardiac monitoring mandatory |
2. Chronic Asthma ā Reliever Therapy
- Starting dose: 1ā2 puffs (100ā200 mcg) MDI/DPI as needed
- Titration: Not applicable (PRN use)
- Usual maintenance dose: 1ā2 puffs up to four times daily when required
- Maximum dose: Should not exceed 8 puffs/day regularly; frequent use indicates need for controller therapy escalation
Clinical Note: Use alongside inhaled corticosteroids (ICS) as per GINA/Indian Asthma Guidelines. Sole reliance on SABA without ICS is associated with increased mortality risk.
3. Exercise-Induced Bronchospasm (EIB) ā Prophylaxis
- Starting dose: 200 mcg (2 puffs MDI) 10ā15 minutes before exercise
- Titration: Not applicable
- Usual maintenance dose: 200 mcg pre-exercise
- Maximum dose: 200 mcg per occasion; if frequent EIB, consider adding LABA or optimising ICS
4. Hyperkalaemia (Adjunctive ā Temporary Intracellular Potassium Shift)
ICU/Emergency setting only
- Starting dose: 10 mg nebulised over 10ā15 minutes
- Titration: May repeat 10 mg dose if K+ remains elevated
- Usual maintenance dose: 10ā20 mg nebulised
- Maximum dose: 20 mg single dose
Clinical Note: Always combine with insulin-dextrose therapy. Effect is temporary (shifts K+ intracellularly). Monitor serum potassium and ECG continuously. Expect K+ reduction of 0.5ā1 mEq/L within 30 minutes.
Secondary Indications ā Adults (Off-label)
Tocolysis in Preterm Labour
| Parameter | Details |
|---|---|
|
Indication
|
Acute tocolysis for preterm labour (24ā34 weeks gestation) |
|
Route
|
IV infusion |
|
Starting dose
|
10 mcg/min |
|
Titration
|
Increase by 5 mcg/min every 10 minutes based on uterine response |
|
Usual range
|
10ā45 mcg/min |
|
Maximum dose
|
80 mcg/min |
|
Duration
|
Up to 48 hours to allow corticosteroid effect for fetal lung maturity |
|
Label status
|
OFF-LABEL
|
|
Specialist only
|
Yes ā Obstetrics specialist supervision mandatory |
|
Evidence basis
|
AIIMS Obstetrics protocols; Indian specialist practice. Nifedipine or atosiban preferred as first-line in current practice due to better safety profile |
Caution: Contraindicated in maternal cardiac disease, preeclampsia, eclampsia, significant antepartum haemorrhage. Monitor maternal HR, BP, fluid balance, serum glucose, and potassium. Risk of pulmonary oedema with IV use.
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
1. Acute Asthma / Acute Bronchospasm
| Age Group | MDI with Spacer | Nebulised | Oral (Syrup/Tablet) |
|---|---|---|---|
|
<2 years
|
Not routinely preferred; if used: 1 puff (100 mcg) with spacer + mask, may repeat every 20 min × 3 in acute setting | 0.15 mg/kg/dose (min 1.25 mg, max 2.5 mg) every 4ā6 hours | Not routinely recommended |
|
2ā5 years
|
1 puff (100 mcg) up to every 4 hours; in acute attack: 2ā4 puffs every 20 min × 3 | 2.5 mg every 4ā6 hours | Syrup: 1ā2 mg (0.1ā0.15 mg/kg) TID |
|
6ā11 years
|
1ā2 puffs every 4ā6 hours PRN; in acute: 4ā6 puffs every 20 min × 3 | 2.5ā5 mg every 4ā6 hours | Tablet: 2 mg TID |
|
≥12 years
|
Adult dosing applies | 2.5ā5 mg every 4ā6 hours | Tablet: 2ā4 mg TID |
Dosing structure:
- Starting dose: As per age table above
- Titration: In acute exacerbation, may give every 20 minutes for up to 3 doses, then every 1ā4 hours as needed
- Usual maintenance dose: PRN use only; 1ā2 puffs every 4ā6 hours
- Maximum dose: Nebulised ā 10 mg/dose in severe acute asthma under monitoring; Oral ā 24 mg/day
Clinical Note: MDI with spacer (and face mask in children <4 years) is as effective as nebulisation and preferred in non-severe exacerbations. Ensure proper technique training.
2. Exercise-Induced Bronchospasm Prophylaxis (Age ≥6 years)
- Starting dose: 100ā200 mcg MDI 15 minutes before exercise
- Titration: Not applicable
- Usual maintenance dose: 200 mcg pre-exercise
- Maximum dose: 200 mcg per occasion
Secondary Indications ā Paediatrics (Off-label)
Hyperkalaemia in Paediatric ICU
| Parameter | Details |
|---|---|
|
Indication
|
Acute hyperkalaemia ā adjunctive treatment |
|
Route
|
Nebulised |
|
Dose
|
2.5 mg (<25 kg) to 5 mg (≥25 kg) nebulised |
|
Frequency
|
May repeat once after 30 minutes |
|
Label status
|
OFF-LABEL
|
|
Specialist only
|
Yes ā PICU setting only |
|
Evidence basis
|
Extrapolated from adult data; used in AIIMS PICU protocols |
Monitoring: Continuous ECG, serum potassium every 1ā2 hours. Always use with insulin-dextrose.
Viral-Induced Wheeze / Bronchiolitis (Age <2 years)
| Parameter | Details |
|---|---|
|
Indication
|
Acute viral wheeze in infants |
|
Route
|
Nebulised or MDI with spacer |
|
Dose
|
2.5 mg nebulised or 2 puffs MDI as therapeutic trial |
|
Duration
|
Single trial; continue only if objective improvement observed |
|
Label status
|
OFF-LABEL ā Routine use not recommended in bronchiolitis (IAP guidelines)
|
|
Specialist only
|
Yes |
|
Evidence basis
|
Variable response; IAP guidelines note limited evidence of benefit in RSV bronchiolitis |
Age Restriction Statement:
Not recommended in children below 2 years of age except under specialist supervision due to limited efficacy data and increased risk of paradoxical bronchospasm. Inhaled route strongly preferred over oral in all age groups.
Not recommended in children below 2 years of age except under specialist supervision due to limited efficacy data and increased risk of paradoxical bronchospasm. Inhaled route strongly preferred over oral in all age groups.
Safety Monitoring in Children:
- Heart rate (tachycardia common)
- Serum potassium if high-dose or prolonged nebulisation
- Tremor, irritability
- Oxygen saturation response
Renal Adjustments
No dose adjustment required in renal impairment.
| eGFR (mL/min/1.73m²) | Adjustment |
|---|---|
| >60 | No adjustment |
| 30ā60 | No adjustment |
| 15ā30 | No adjustment; monitor for hypokalaemia |
| <15 or dialysis | No adjustment; use with caution; monitor potassium |
Note: Salbutamol is not significantly renally excreted. However, patients with severe CKD may be more susceptible to hypokalaemia and cardiovascular effects. Use lowest effective dose.
Hepatic adjustment
Contraindications
- Known hypersensitivity to salbutamol or any excipient in formulation
- Uncontrolled severe cardiac arrhythmias (tachyarrhythmias)
- Hypertrophic obstructive cardiomyopathy
- Concurrent use with non-selective beta-blockers (e.g., propranolol, carvedilol) ā antagonises bronchodilator effect
- Tocolysis-specific: Maternal cardiac disease, eclampsia, severe preeclampsia, intrauterine infection, intrauterine fetal death, antepartum haemorrhage requiring immediate delivery
Cautions
- Cardiovascular disease (ischaemic heart disease, heart failure, arrhythmias) ā increased risk of tachycardia, palpitations
- Hypertension ā may cause transient BP elevation
- Diabetes mellitus ā may elevate blood glucose; monitor in diabetic patients on high-dose or IV therapy
- Hyperthyroidism ā may exacerbate cardiovascular effects
- Seizure disorders ā potential CNS stimulation at high doses
- Hypokalaemia or concurrent use of potassium-lowering drugs
- Phaeochromocytoma (theoretical concern)
- Paradoxical bronchospasm ā discontinue immediately if worsening wheeze after inhalation
- Frequent SABA use (>2 days/week) ā indicates poor asthma control; reassess controller therapy
Pregnancy
| Parameter | Details |
|---|---|
|
Overall safety
|
Considered relatively safe; one of the most commonly used bronchodilators in pregnant women with asthma |
|
Risk category
|
US legacy Category C (crosses placenta; no controlled human studies showing teratogenicity) |
|
Indian practice
|
First-line reliever for asthma in pregnancy per IAP/FOGSI guidelines |
|
When to use
|
Inhaled route for asthma management ā benefit clearly outweighs theoretical risk |
|
Preferred alternatives
|
None required for inhaled use; salbutamol is standard of care |
|
Monitoring
|
Maternal: heart rate, blood pressure. Fetal: heart rate monitoring if high-dose or IV use |
|
Tocolysis caution
|
IV use associated with maternal tachycardia, hypotension, pulmonary oedema, hypokalaemia. Nifedipine preferred as first-line tocolytic in current Indian practice |
Key Point: Uncontrolled asthma poses greater risk
Lactation
| Parameter | Recommendation |
|---|---|
| Compatibility | Compatible with breastfeeding |
| Drug levels in milk | Low; clinically insignificant amounts excreted |
| Preferred alternatives | None needed; salbutamol is standard for breastfeeding mothers with asthma |
| Infant monitoring | Observe for irritability, feeding difficulties, or tremor if high maternal doses used |
Elderly
| Parameter | Recommendation |
|---|---|
| Starting dose | Lower end of adult dosing range (100 mcg MDI; 2.5 mg nebulised) |
| Titration | Slower; assess cardiovascular tolerance before dose increase |
| Specific risks | Tachycardia, palpitations, arrhythmias (especially in underlying IHD or AF); hypokalaemia; tremor more pronounced |
| Additional caution | Use lowest effective dose; monitor potassium if on diuretics; avoid oral formulations if possible |
Major drug interactions
| Drug | Interaction | Recommendation |
|---|---|---|
| Non-selective beta-blockers (propranolol, carvedilol, nadolol) | Antagonise bronchodilatory effect; may precipitate severe bronchospasm | AVOID combination. Use cardioselective beta-blockers (bisoprolol, metoprolol) with caution if essential |
| MAO inhibitors | Potentiation of cardiovascular effects; risk of hypertensive crisis | Avoid salbutamol within 14 days of MAO inhibitor use |
| Tricyclic antidepressants | Enhanced cardiovascular effects; risk of arrhythmias | Use with caution; monitor heart rate and blood pressure |
| Digoxin | Hypokalaemia induced by salbutamol may increase digoxin toxicity | Monitor serum potassium and digoxin levels |
Moderate drug interactions
| Drug | Interaction | Recommendation |
|---|---|---|
| Loop diuretics (furosemide) | Additive hypokalaemia | Monitor serum potassium; correct deficits |
| Thiazide diuretics | Additive hypokalaemia | Monitor serum potassium |
| Systemic corticosteroids | Additive hypokalaemia, especially with high doses | Monitor potassium in prolonged use |
| Theophylline/Aminophylline | Additive tachycardia, tremor, CNS stimulation | Use together with monitoring; dose adjustment rarely needed |
| Antidiabetic agents (insulin, sulphonylureas) | Salbutamol may cause hyperglycaemia, reducing efficacy | Monitor blood glucose; may need temporary dose adjustment |
| Xanthine derivatives | Additive cardiac stimulation | Monitor for tachyarrhythmias |
Common Adverse effects
- Fine tremor (especially hands)
- Palpitations
- Tachycardia
- Headache
- Muscle cramps
- Nervousness/restlessness
- Throat irritation and dry mouth (inhaled forms)
- Transient hypokalaemia
Serious Adverse effects
| Adverse Effect | Clinical Notes |
|---|---|
| Paradoxical bronchospasm | Discontinue immediately; switch to alternative bronchodilator |
| Severe hypokalaemia | Risk of cardiac arrhythmias; especially with high-dose nebulisation or IV use |
| Cardiac arrhythmias | Including atrial fibrillation, ventricular ectopics; monitor ECG in high-risk patients |
| QTc prolongation | Rare; risk increased with hypokalaemia or concurrent QT-prolonging drugs |
| Lactic acidosis | Very rare; reported with high-dose IV infusions |
| Pulmonary oedema | Associated with IV tocolytic use; avoid in cardiac disease |
| Myocardial ischaemia | Risk in patients with underlying coronary artery disease |
Monitoring requirements
| Phase | Parameters |
|---|---|
| Baseline | Heart rate, blood pressure, serum potassium (if high-dose or IV anticipated), blood glucose (diabetics) |
| During acute management | Oxygen saturation, respiratory rate, peak expiratory flow rate, heart rate, ECG (if IV used) |
| High-dose/IV use | Continuous cardiac monitoring, serum potassium every 4ā6 hours, blood glucose |
| Long-term use | Frequency of SABA use (>2 days/week indicates poor control); inhaler technique assessment; asthma control parameters |
Brands in India
| Brand Name | Manufacturer | Notes |
|---|---|---|
| Asthalin | Cipla | MDI, Rotacaps, Nebuliser solution, Tablets, Syrup |
| Ventorlin | GlaxoSmithKline | MDI, Rotacaps, Respules |
| Salbair | Lupin | MDI, Nebuliser solution |
| Salbetol | FDC Ltd | Tablets, Syrup |
| Salbutamol (Generic) | Various | Available across formulations |
FDC Products:
- Duolin (Salbutamol + Ipratropium) ā Cipla
- Combimist (Salbutamol + Ipratropium) ā Lupin
- Levolin (Levosalbutamol) ā Cipla (R-isomer variant)
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| MDI 100 mcg (200 doses) | ā¹50āā¹100 |
| DPI Rotacaps (30 caps) | ā¹30āā¹70 |
| Nebuliser Respules (2.5 mg/2.5 mL) per unit | ā¹3āā¹6 |
| Nebuliser Solution 15 mL (5 mg/mL) | ā¹25āā¹40 |
| Tablets (strip of 10) | ā¹5āā¹15 |
| Syrup 60 mL | ā¹15āā¹35 |
| Injection ampoule | ā¹10āā¹30 |
Regulatory Note: Listed under NLEM 2022; prices regulated by NPPA for scheduled formulations. Available under government supply programmes.
Clinical pearls
- Inhaled route always preferred: Oral and parenteral routes have higher systemic side effects with no added bronchodilator efficacy. Reserve oral forms for patients who cannot use inhalers despite training.
- Spacer is essential: Always use spacer device with MDI for optimal drug delivery to lower airways, especially in children and elderly. Without spacer, >80% of drug deposits in oropharynx.
- SABA overuse signals poor control: If patient uses reliever >2 times/week (excluding pre-exercise use), reassess ICS adherence, inhaler technique, and consider stepping up controller therapy.
- Hyperkalaemia use is adjunctive only: Nebulised salbutamol provides temporary intracellular potassium shift (onset 15ā30 min, duration 2ā4 hours). Always use with insulin-glucose and arrange definitive therapy.
- Cardiac caution: In patients with IHD or arrhythmias, use lowest effective dose. Consider ipratropium as alternative or add-on to reduce salbutamol requirement.
- Combination with ipratropium: In acute severe asthma or COPD exacerbation, adding ipratropium to salbutamol provides additive bronchodilation and is recommended in emergency protocols.
Version
RxIndia v1.0 ā 04 May 2025
Reference
- CDSCO Drug Database and Product Inserts
- Indian Pharmacopoeia 2022
- National List of Essential Medicines (NLEM) 2022
- National Asthma Control Programme (India)
- AIIMS Treatment Guidelines (Emergency Medicine, Paediatrics)
- API Textbook of Medicine (11th Edition)
- IAP Asthma Guidelines
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- AIIMS Obstetrics Protocols (for tocolysis reference)
- PGI Chandigarh PICU Protocols
āļø
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.